A broader protein vision

Waters teams with Proteome Software for protein visualization
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MILFORD, Mass.—Waters Corp. and Portland, Ore.-based Proteome Software Inc. recently announced a collaboration aimed at providing compatibility between Waters' IdentityE High Definition proteomics system and Proteome's Scaffold 2.1 visualization software. The intent of the collaboration is to allow researchers to make better use of the very rich and complex data sets generated from Waters' proprietary MC-MSE technology through more accurate protein identifications.

"What has plagued this field and LC/MS are reliable, reproducible techniques and the algorithms to identify the proteins in a complex biological mixture," says James Langride, Ph.D., proteomics business director with Waters. "The ability of Scaffold to visualize our IdentityE results will allow scientists to maximize the information from our proprietary LC-MSE technology."

According to Mark Turner, president and co-founder of Proteome Software, working with Waters provides his company with an opportunity to extend the value of Scaffold 2.1, while also pushing the envelope a bit as it works with the richer and deeper data sets provided by IndentityE.

"I really can't emphasize enough the revolutionary nature of the way Waters is running their mass spec," Turner notes. "It is a different method and it requires the use of IdentityE for the data it generates. They thought there would be some kind of advantage to be able to visualize their data using our software."

With the Waters deal, Proteome Software has some work ahead of it since the data produced by the Waters instruments and collected by IdentityE is atypical of other mass spec data sets. As a result, the integration of the two systems should take some time and both companies are targeting a late fourth quarter roll-out. DDN

About the Author

Related Topics

Published In

Volume 4 - Issue 9 | September 2008

September 2008

September 2008 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue